Calidi Biotherapeutics (CLDI) Other Non-Current Liabilities (2021 - 2026)
Calidi Biotherapeutics (CLDI) posted quarterly Other Non-Current Liabilities of $115000.0 for Q4 2025, down 10.16% year-over-year from $128000.0 in Q4 2024, and down 42.79% quarter-over-quarter from $201000.0 in Q3 2025.
Calidi Biotherapeutics (CLDI) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Calidi Biotherapeutics' Other Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $115000.0 for Q4 2025.
- In Q4 2025, Other Non-Current Liabilities fell 10.16% year-over-year to $115000.0; the TTM figure through Dec 2025 stood at $115000.0 (down 10.16% YoY), while the FY2025 annual figure was $115000.0, down 10.16% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $115000.0, down from $201000.0 in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $30.3 million in Q4 2022, with the low at $50000.0 in Q2 2024.
- The 5-year median for Other Non-Current Liabilities is $647000.0 (2024), against an average of $3.1 million.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities jumped 306.23% in 2022, then slumped 97.95% in 2023.
- Calidi Biotherapeutics' Other Non-Current Liabilities stood at $7.5 million in 2021, then surged by 306.23% to $30.3 million in 2022, then plunged by 97.95% to $623000.0 in 2023, then tumbled by 79.45% to $128000.0 in 2024, then dropped by 10.16% to $115000.0 in 2025.
- Business Quant data shows CLDI's Other Non-Current Liabilities at $115000.0 in Q4 2025, $201000.0 in Q3 2025, and $103000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 68,000.00 |
| Dec 31, 2025 | 115,000.00 |
| Sep 30, 2025 | 201,000.00 |
| Jun 30, 2025 | 103,000.00 |
| Mar 31, 2025 | 87,000.00 |
| Dec 31, 2024 | 128,000.00 |
| Sep 30, 2024 | 176,000.00 |
| Jun 30, 2024 | 50,000.00 |
| Mar 31, 2024 | 647,000.00 |
| Dec 31, 2023 | 623,000.00 |
| Sep 30, 2023 | 2.95 Mn |
| Jun 30, 2023 | 1.94 Mn |
| Mar 31, 2023 | 656,500.00 |
| Dec 31, 2022 | 30.34 Mn |
| Sep 30, 2022 | 885,000.00 |
| Jun 30, 2022 | 1.35 Mn |
| Mar 31, 2022 | 5.37 Mn |
| Dec 31, 2021 | 7.47 Mn |